000			03709nam a22005657a 4500
008			160113s20152015 xxu||||| |||| 00| 0 eng d
022			_a1465-6566
040			_aOvid MEDLINE(R)
099			_a25633751
245			_aPrasugrel hydrochloride for the treatment of acute coronary syndromes. [Review]
251			_aExpert Opinion on Pharmacotherapy. 16(4):585-96, 2015 Mar.
252			_aExpert Opin Pharmacother. 16(4):585-96, 2015 Mar.
253			_aExpert opinion on pharmacotherapy
266			_d2016-01-13
520			_aAREAS COVERED: This review describes prasugrel chemistry, pharmacokinetics, pharmacodynamics and clinical studies. In a Phase III randomized clopidogrel-controlled trial, prasugrel improved cardiovascular outcome (risk reduction of cardiovascular death, non-fatal heart attack and non-fatal stroke) at the cost of increased major and fatal bleeding complications. Prasugrel, in combination with aspirin, has been approved by European and American regulatory agencies for the prevention of atherothrombotic events in patients with ACS who undergo percutaneous coronary intervention (PCI).
520			_aEXPERT OPINION: Prasugrel is effective for managing ACS patients with planned PCI and it offers an alternative with potential benefits over clopidogrel. Prasugrel is currently challenged by ticagrelor, a P2Y12 receptor antagonist with different pharmacokinetic/pharmacodynamic properties. The superiority of one drug to the other cannot be reliably estimated from the current trials. Ongoing randomized and observational studies may help to provide valuable information on the safety and efficacy of these two drugs and their respective places with ACS patients.
520			_aINTRODUCTION: P2Y12 receptor antagonists, by inhibiting platelet activation and subsequent aggregation, are critical to prevent ischemic event recurrence after an acute coronary syndrome (ACS). Prasugrel is a third-generation thienopyridine whose metabolites target the P2Y12 receptor. Compared with clopidogrel, prasugrel has a more potent, faster in onset, and more consistent P2Y12 receptor inhibition.
546			_aEnglish
650			_a*Acute Coronary Syndrome/dt [Drug Therapy]
650			_a*Piperazines/tu [Therapeutic Use]
650			_a*Platelet Aggregation Inhibitors/tu [Therapeutic Use]
650			_a*Purinergic P2Y Receptor Antagonists/tu [Therapeutic Use]
650			_a*Thiophenes/tu [Therapeutic Use]
650			_aAnimals
650			_aAspirin/tu [Therapeutic Use]
650			_aClinical Trials, Phase III as Topic
650			_aDrug Therapy, Combination
650			_aHumans
650			_aPercutaneous Coronary Intervention
650			_aPiperazines/pd [Pharmacology]
650			_aPiperazines/pk [Pharmacokinetics]
650			_aPlatelet Aggregation Inhibitors/pd [Pharmacology]
650			_aPlatelet Aggregation Inhibitors/pk [Pharmacokinetics]
650			_aPractice Guidelines as Topic
650			_aPurinergic P2Y Receptor Antagonists/pd [Pharmacology]
650			_aPurinergic P2Y Receptor Antagonists/pk [Pharmacokinetics]
650			_aRandomized Controlled Trials as Topic
650			_aThiophenes/pd [Pharmacology]
650			_aThiophenes/pk [Pharmacokinetics]
650			_aTiclopidine/aa [Analogs & Derivatives]
650			_aTiclopidine/tu [Therapeutic Use]
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
657			_aReview
700			_aLhermusier, Thibault
700			_aWaksman, Ron
790			_aLhermusier T, Waksman R
856			_uhttp://dx.doi.org/10.1517/14656566.2015.1005602 _zhttp://dx.doi.org/10.1517/14656566.2015.1005602
942			_cART _dJournal article
999			_c12465 _d12465